DKP21102_C

DKP21102_C is an investigational pharmaceutical product studied in the context of mixed dyslipidemia, specifically for patients whose low-density lipoprotein cholesterol (LDL-C) is adequately controlled but who continue to have elevated triglyceride and/or unregulated high-density lipoprotein cholesterol (HDL-C) levels. It has been evaluated as part of a combination therapy regimen in Phase 3 clinical trials, where it was compared to other formulations such as DKP21102_A and DKP21102_B. The drug was developed by Dongkwang Pharm. The precise mechanism of action, molecular composition, and modality are not specified in available public sources; however, its use in dyslipidemia suggests it targets lipid metabolism pathways[1][2].